MorphoSys AG (LTS:0NDV)
€ 66.8 0 (0%) Market Cap: 2.53 Bil Enterprise Value: 2.49 Bil PE Ratio: 0 PB Ratio: 51.57 GF Score: 45/100

MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call Transcript

Jan 13, 2020 / 03:00PM GMT
Release Date Price: €125.3 (-7.56%)
Operator

Ladies and gentlemen, welcome to the conference call of MorphoSys and Incyte. (Operator Instructions) And the conference is being recorded. (Operator Instructions)

Now I would like to turn the conference over to Sarah Fakih. Please go ahead.

Sarah Fakih
MorphoSys AG - VP & Head of Corporate Communications and IR

Thank you. Good morning, good afternoon, and welcome to our joint conference call and webcast to discuss the announcement of our global partnership deal with Incyte which was signed yesterday evening Pacific time. My name is Sarah Fakih. I'm the Head of Corporate Communications and Investor Relations at MorphoSys.

With me on the call today are Jean-Paul Kress, our Chief Executive Officer; and Jens Holstein, our Chief Financial Officer. And we are very pleased to be joined by Hervé Hoppenot, the CEO of Incyte, Christiana Stamoulis, Incyte CFO; and Mike Booth, Incyte Head of Investor Relations.

Before we start, I would like to remind you that during this conference call, we may discuss certain forward-looking statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot